More

    [Pangyo Bio & Medical] Organoid Science establishes GMP center to produce organoid-based regenerative therapy

    Organoid Science
    opened the GMP Center in Gwangmyeong-si, Gyeonggi-do on December 8. | Photo courtesy of Organoid Science

    Organoid Science (CEO Jongman Yoo), an innovative company specializing in organoids, announced that it opened a GMP Center located in Gwangmyeong-si, Gyeonggi-do last December.

    Organoid Science, which has secured its own GMP facility, is expected to produce cell therapy reagents for clinical trials, further accelerating the clinical progress of organoid-based regenerative therapies in rare and incurable diseases.

    Currently, Organoid Science’s GMP Center has secured the first clinical-grade organoid-based regenerative therapy production capacity in Korea and is aiming to obtain two licenses for advanced biopharmaceutical manufacturing and cell processing facilities within the first half of this year.

    ‘ATORM’, an organoid-based regenerative therapy owned by Organoid Science as its original technology, is a platform that regenerates damaged tissues and enables fundamental treatment rather than symptom relief. Based on this technology and GMP production facilities and systems, we have not only expanded the production base for therapeutic products, but also laid the foundation for becoming a base for the 3D cell therapy CDMO (Consignment Development and Manufacturing) business, which has recently been in the spotlight in the bio industry.

    According to an official at Organoid Science, “By securing the largest organoid-based cell therapy GMP center in the country, we will resolve issues related to production and quality by securing pharmaceutical GMP certification and provide our own one-stop solution for production-licensing-sales.”

    Jong-man Yoo, CEO of Organoid Science, said, “With the opening of this GMP, not only can smooth clinical trials progress, but mass production of organoid regeneration treatments will become possible in the future.” He added, “This GMP center is a global-level center capable of developing and producing CMC specialized for 3D cell therapy. “We will develop it into a forward base for the CDMO business,” he expressed his ambition.

    Source:  Pangyo Techno Valley Official Newsroom

    → Go to ‘Asia Innovation Hub Pangyo Techno Valley 2022’ news